VBI Vaccines (NASDAQ:VBIV) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a report issued on Thursday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Trading Down 56.8 %

Shares of VBIV stock traded down $0.04 during trading hours on Thursday, hitting $0.03. The stock had a trading volume of 3,169,517 shares, compared to its average volume of 3,651,473. VBI Vaccines has a one year low of $0.06 and a one year high of $1.35. The stock’s 50-day moving average price is $0.56 and its two-hundred day moving average price is $0.60.

VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.02). VBI Vaccines had a negative net margin of 881.79% and a negative return on equity of 525.42%. The firm had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $2.85 million.

VBI Vaccines Company Profile

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.